Rizatriptan (
MAXALT, a registered trademark of Merck & Co. Inc.) is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of
migraine. This randomized, open-label, crossover outpatient study assessed the preference of 481 patients for
rizatriptan 10-mg rapidly disintegrating
tablets versus
sumatriptan (
IMIGRAN, a registered trademark of GlaxoWellcome PLC) 50-mg
tablets in the treatment of a single
migraine attack with each
therapy. Almost twice as many patients preferred
rizatriptan 10-mg rapidly disintegrating
tablet to
sumatriptan 50-mg
tablet (64.3 vs. 35.7%, p < or = 0.001). Faster relief of
headache pain was the most important reason for the preference, cited by 46.9% of patients preferring
rizatriptan and 43.4% of patients who preferred
sumatriptan.
Headache relief at 2 h was 75.9% with
rizatriptan and 66.6% with
sumatriptan (p < or = 0.001), with
rizatriptan being superior to
sumatriptan within 30 min of dosing. Fifty-five percent of patients were
pain free 2 h after
rizatriptan, compared with 42.1% treated with
sumatriptan (p < or = 0.001),
rizatriptan being superior within 1 h of treatment. Forty-one percent of patients taking
rizatriptan were
pain free at 2 h and had no recurrence or need for additional medication, compared to 32.3% of patients on
sumatriptan.
Rizatriptan was also superior to
sumatriptan in terms of the proportions of patients with no
nausea,
phonophobia or
photophobia, and patients with normal function 2 h
after treatment intake (p < 0.05). More patients were (completely, very or somewhat) satisfied 2 h
after treatment with
rizatriptan (73.3%) than 2 h
after treatment with
sumatriptan (59.0%) (p < or = 0.001). Additionally, 2 h after the dose, more patients found
rizatriptan to be very convenient, convenient or somewhat convenient (87.2%) than they did
sumatriptan (76.3%) (p < or = 0.001). Both active treatments were well tolerated. The most common side effects with
rizatriptan and
sumatriptan were
nausea (6.6 and 6.9% of patients, respectively),
dizziness (6.1 and 5.8%) and
somnolence (7.4 and 6.7%).